ST-113 is being assessed as a treatment for open-angle glaucoma. Credit: Inside Creative House / Shutterstock.com.

Stuart Therapeutics and Glaukos have signed a licence agreement for the former’s ST-113 drug candidate for neuroprotection in glaucoma.

Glaukos has received exclusive global rights for the development and commercialisation of the patented pre-clinical asset.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The drug candidate has shown the potential to deliver neuroprotection and neuro-repair of optic nerve axons when tested in animals.

Stuart will receive an upfront payment, along with additional development and sales-related milestone payments and royalties. 

Glaukos will be responsible for all development costs of ST-113. 

See Also:

ST-113 is being evaluated as a therapy for open-angle glaucoma, including normal tension glaucoma.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It is a synthesised collagen mimetic peptide that restores impaired helical collagen selectively in the extracellular matrix. 

According to Stuart’s preclinical research findings, ST-113 can restore collagen’s structural and cell signalling functions within the optic nerve, which will lead to decreased inflammation and restored nerve health.

Stuart has been working on ST-113 for glaucoma, which has included creating new endpoints suitable for a neuroprotective approach to the disease.

Stuart Therapeutics president and CEO Eric Schlumpf stated: “We wanted to partner with a leader in glaucoma therapeutics to bring this innovative drug candidate to the millions of glaucoma patients across the world, and Glaukos has delivered in this important disease area. 

“They bring critical focus on novel therapies, capabilities in drug product design and delivery and commercial strength worldwide.”

This content was updated on 25 January 2024